Jennifer Burstein Sells 1,700 Shares of Loxo Oncology, Inc. (LOXO) Stock

Loxo Oncology, Inc. (NASDAQ:LOXO) VP Jennifer Burstein sold 1,700 shares of the stock in a transaction dated Monday, October 30th. The shares were sold at an average price of $87.19, for a total transaction of $148,223.00. Following the completion of the sale, the vice president now directly owns 1,700 shares in the company, valued at $148,223. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Jennifer Burstein also recently made the following trade(s):

  • On Monday, September 18th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $89.10, for a total transaction of $151,470.00.
  • On Monday, August 14th, Jennifer Burstein sold 1,700 shares of Loxo Oncology stock. The shares were sold at an average price of $73.73, for a total transaction of $125,341.00.

Loxo Oncology (NASDAQ:LOXO) last released its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.99) by ($0.15). During the same period in the previous year, the business earned ($0.77) earnings per share.

COPYRIGHT VIOLATION WARNING: This news story was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States & international copyright and trademark law. The legal version of this news story can be accessed at https://www.com-unik.info/2017/11/03/jennifer-burstein-sells-1700-shares-of-loxo-oncology-inc-loxo-stock.html.

A number of brokerages recently commented on LOXO. BidaskClub raised shares of Loxo Oncology from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Zacks Investment Research raised shares of Loxo Oncology from a “hold” rating to a “buy” rating and set a $82.00 price objective on the stock in a research note on Wednesday, August 9th. Stifel Nicolaus reissued a “buy” rating and issued a $94.00 price objective (up from $71.00) on shares of Loxo Oncology in a research note on Thursday, August 10th. BTIG Research reissued a “buy” rating and issued a $75.00 price objective on shares of Loxo Oncology in a research note on Thursday, August 3rd. Finally, Ifs Securities reissued an “outperform” rating on shares of Loxo Oncology in a research note on Tuesday, August 8th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $80.02.

A number of institutional investors and hedge funds have recently modified their holdings of LOXO. Ameritas Investment Partners Inc. increased its stake in Loxo Oncology by 31.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 419 shares in the last quarter. Legal & General Group Plc increased its stake in Loxo Oncology by 8.4% in the 1st quarter. Legal & General Group Plc now owns 3,682 shares of the biopharmaceutical company’s stock worth $154,000 after purchasing an additional 284 shares in the last quarter. BNP Paribas Arbitrage SA increased its stake in Loxo Oncology by 4,388.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 2,244 shares of the biopharmaceutical company’s stock worth $180,000 after purchasing an additional 2,194 shares in the last quarter. SG Americas Securities LLC purchased a new position in Loxo Oncology in the 2nd quarter worth about $228,000. Finally, Marshall Wace LLP purchased a new position in Loxo Oncology in the 2nd quarter worth about $233,000.

Loxo Oncology Company Profile

Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.

Insider Buying and Selling by Quarter for Loxo Oncology (NASDAQ:LOXO)

What are top analysts saying about Loxo Oncology Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Loxo Oncology Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit